Literature DB >> 24980106

Enhancing exposure of protein therapeutics.

John M Beals1, Armen B Shanafelt2.   

Abstract

Therapeutic proteins have made a major impact on medicine, with significant expansion in the past two decades. The medicinal attributes of these agents, particularly their efficacy and often their safety profile, make protein therapeutics attractive, despite the general necessity of invasive (parenteral) delivery. This perceived hurdle has been a primary component in limiting expansion of this class of drug therapies. Strategies that reduce the frequency of administration directly provide greater convenience to the patient, and potentially greater efficacy, that can yield a significant treatment advantage.: � 2006 Elsevier Ltd . All rights reserved.

Entities:  

Year:  2006        PMID: 24980106     DOI: 10.1016/j.ddtec.2006.03.001

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  5 in total

Review 1.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

2.  Site-specific protein modifications through pyrroline-carboxy-lysine residues.

Authors:  Weijia Ou; Tetsuo Uno; Hsien-Po Chiu; Jan Grünewald; Susan E Cellitti; Tiffany Crossgrove; Xueshi Hao; Qian Fan; Lisa L Quinn; Paula Patterson; Linda Okach; David H Jones; Scott A Lesley; Ansgar Brock; Bernhard H Geierstanger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

3.  Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier® insulin.

Authors:  André M M Miltenburg; Marita Prohn; Jacqueline H M van Kuijk; Renger G Tiessen; Martin de Kort; Rob J W Berg
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

4.  Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.

Authors:  Thierry Huet; Olivier Kerbarh; Dominique Schols; Pascal Clayette; Cécile Gauchet; Guy Dubreucq; Loïc Vincent; Heidi Bompais; Romain Mazinghien; Olivier Querolle; Arnaud Salvador; Jérôme Lemoine; Bruno Lucidi; Jan Balzarini; Maurice Petitou
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

5.  Crystal polymorphism of protein GB1 examined by solid-state NMR spectroscopy and X-ray diffraction.

Authors:  Heather L Frericks Schmidt; Lindsay J Sperling; Yi Gui Gao; Benjamin J Wylie; John M Boettcher; Scott R Wilson; Chad M Rienstra
Journal:  J Phys Chem B       Date:  2007-12-04       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.